Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mitsubishi Tanabe Lines Up Trials For Hepatitis C Therapy

This article was originally published in PharmAsia News

Executive Summary

TOKYO - As Massachusetts-based Vertex Pharmaceuticals this month launches a closely watched Phase III trial of investigational hepatitis C therapy telaprevir, Osaka-based Mitsubishi Tanabe Pharma has been enrolling Japanese patients for three Phase I/II trials of the drug, an oral protease inhibitor

You may also be interested in...

PharmAsia News Notable Notes: WuXi Confronts Chinese Macro Challenges

WuXi Pharma has systems in place to soften the impact of cost inflation issues expected to impact the Chinese pharma industry, according to Oppenheimer analyst Charles Rhyee

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts